Answers are grounded in this paper and cite their sources.
Background:In recent years, the incidence of migraine has increased year by year, and it is still the second largest cause of disability in the world. Migraine accounts for 5.6% of the global disease burden, exceeding the sum of all other nervous system diseases, because its onset often begins at the age of 25-34 and reaches its peak at the age of 35-39, which seriously affects people's work ability and causes a serious burden to society and families. However, at present, the clinical efficacy of various drugs are not ideal, and there are adverse reactions. Therefore, it is urgent to research and develop drugs with good safety and definite curative effect. Purpose: A large number of clinical studies showed that Smilax glabra had a good effect on treating migraine. However, there is no content of Smilax glabra on treating migraine in Chinese medicine books, and there is no research report on Smilax glabra on treating migraine and related active ingredients in modern research. Therefore, we intend to adopt modern analysis and pharmacological methods to clarify the therapeutic effects of Smilax glabra on migraine and related active components. Methods: The active components of Rhizoma Smilacis Glabrae in preventing and treating migraine were studied by network pharmacological analysis and brain tissue chemical detection. The analgesic effect of Smilax glabra, astilbin and astilbin vesicles on writhing induced by acetic acid and pain threshold of heat stimulated mice was studied. To study the effects of Smilax glabra, astilbin and astilbin vesicles on migraine model animals.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: